IL-17 抑制剂与自身免疫性疾病患者高血压的关系：随机对照试验的系统综述和元分析》。

IF 2.6 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI:10.1097/FJC.0000000000001547

Kexin Jiang, Yuheng Jia, Li Chen, Fangyang Huang, Mao Chen

引用次数: 0

摘要

IL-17抑制剂对自身免疫性疾病患者血压的影响仍无定论。我们的目的是通过对随机安慰剂对照试验（RCT）进行荟萃分析，研究接受IL-17抑制疗法的自身免疫性疾病患者罹患高血压的风险。我们从 PubMed、Embase 和 ClinicalTrials.gov 获得了综合数据。我们计算了高血压的发病率，分析了危险比（HRs）和95%置信区间（CIs），并用Ι^2统计量评估了异质性。序列分析确保了结论的可靠性。在30项涉及9909名不同自身免疫性疾病患者的抗IL-17药物治疗研究中，我们的荟萃分析显示高血压风险显著增加（RR 1.69，CI 1.24-2.31，P=0.001），试验序列分析有力地支持了这一结论。在四种药物（secukinumab、ixekizumab、bimekizumab和brodalumab）中，只有secukinumab与高血压有明显关联。患有各种原发性自身免疫性疾病的患者，尤其是银屑病关节炎患者，患高血压的可能性更高；在风湿性关节炎患者队列中，抗IL-17药物不会增加高血压风险。治疗时间延长与高血压风险增加有关。按性别分类，与男性占主导地位的研究相比，女性占主导地位的研究显示出更高的高血压风险比。这突出表明抗IL-17治疗会增加高血压风险，强调在管理自身免疫性疾病患者时需要格外谨慎。(由 PROSPERO 注册，CRD42016053112）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of Interleukin-17 Inhibitors With Hypertension in Patients With Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cardiovascular Pharmacology 医学-心血管系统

CiteScore

5.10

自引率

3.30%

发文量

367

审稿时长

1 months

期刊介绍： Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.